DBV Technologies SA – (NASDAQ:DBVT) saw unusually-high trading volume on Monday . Approximately 154,965 shares changed hands during mid-day trading, an increase of 202% from the previous session’s volume of 51,384 shares.The stock last traded at $33.95 and had previously closed at $33.52.

Several brokerages have weighed in on DBVT. Jefferies Group reaffirmed a “buy” rating on shares of DBV Technologies SA – in a report on Wednesday, June 8th. Zacks Investment Research raised shares of DBV Technologies SA – from a “sell” rating to a “hold” rating in a report on Wednesday, June 8th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. DBV Technologies SA – presently has an average rating of “Buy” and a consensus price target of $50.52.

The stock’s 50 day moving average is $33.59 and its 200-day moving average is $31.23. The company’s market cap is $1.56 billion.

A number of institutional investors have modified their holdings of the company. New York State Common Retirement Fund acquired a new position in shares of DBV Technologies SA – during the fourth quarter valued at $2,551,000. RS Investment Management Co. LLC raised its stake in DBV Technologies SA – by 1.7% in the fourth quarter. RS Investment Management Co. LLC now owns 502,860 shares of the company’s stock valued at $18,259,000 after buying an additional 8,220 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in DBV Technologies SA – by 0.9% in the fourth quarter. Jennison Associates LLC now owns 721,775 shares of the company’s stock valued at $26,208,000 after buying an additional 6,578 shares in the last quarter.

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.